Clinical Trial Update: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on adalimumab for uveitis refractory to conventional therapy, covering Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Heidelberg University | Conditions: Uveitis | Phase 2, Phase 3 | Status: UNKNOWN